1y return+124.5%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2023: $218 against $157 in the S&P 500.2
Vestal Point Capital, LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| BMRNBioMarin Pharmaceutical Inc | $344.8M | 8.1% | +68.5% |
| NBIXNeurocrine Biosciences Inc | $316.8M | 7.4% | +50.4% |
| ABVXAbivax SA | $313.1M | 7.3% | +56.6% |
| UTHRUnited Therapeutics Corp | $235.7M | 5.5% | +480.0% |
| ELVNEnliven Therapeutics Inc | $203.0M | 4.7% | +23.1% |
| NRIXNurix Therapeutics Inc | $195.3M | 4.6% | +23.8% |
| BCAXBicara Therapeutics Inc | $155.9M | 3.6% | −3.2% |
| TSHATaysha Gene Therapies Inc | $132.2M | 3.1% | +7.9% |
| ARWRArrowhead Pharmaceuticals Inc | $128.4M | 3.0% | −30.8% |
| ABTAbbott Laboratories | $127.0M | 3.0% | New |
| ZBHZimmer Biomet Holdings Inc | $120.5M | 2.8% | +636.8% |
| IRONDisc Medicine Inc | $113.4M | 2.6% | +121.4% |
| GLUEMonte Rosa Therapeutics Inc | $111.3M | 2.6% | +27.7% |
| PODDInsulet Corp | $102.0M | 2.4% | +1224.1% |
| Ascendis Pharma A/SCUSIP K08588103 | $100.0M | 2.3% | New |
| AstraZeneca PLCCUSIP G0593M107 | $85.3M | 2.0% | +350.0% |
| SNYSanofi SA | $85.3M | 2.0% | +42.9% |
| RVMDRevolution Medicines Inc | $84.3M | 2.0% | −81.1% |
| BCRXBioCryst Pharmaceuticals Inc | $83.0M | 1.9% | +18.1% |
| DYNDyne Therapeutics Inc | $75.0M | 1.8% | −15.6% |
| NKTRNektar Therapeutics | $69.8M | 1.6% | +250.9% |
| GMEDGlobus Medical Inc | $67.2M | 1.6% | +39.2% |
| TARSTarsus Pharmaceuticals Inc | $66.1M | 1.5% | +425.0% |
| Immatics NVCUSIP N44445109 | $62.6M | 1.5% | |
| TRVITrevi Therapeutics Inc | $57.8M | 1.4% | +43.1% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| RVMDRevolution Medicines Inc | June 30, 2025 | +409.1% | $84.3M |
| GLUEMonte Rosa Therapeutics Inc | September 30, 2025 | +226.6% | $111.3M |
| TSHATaysha Gene Therapies Inc | June 30, 2025 | +194.8% | $132.2M |
| uniQure NVCUSIP N90064101 | March 31, 2026 | +181.7% | $43.1M |
| ELVNEnliven Therapeutics Inc | June 30, 2025 | +153.0% | $203.0M |
| DYNDyne Therapeutics Inc | March 31, 2025 | +112.3% | $75.0M |
| ABVXAbivax SA | September 30, 2025 | +57.0% | $313.1M |
| TRVITrevi Therapeutics Inc | March 31, 2026 | +56.3% | $57.8M |
| Crescent Biopharma IncCUSIP G2545C104 | December 31, 2025 | +51.8% | $29.3M |
| RAPPRapport Therapeutics Inc | September 30, 2025 | +40.3% | $30.4M |
Sold off last quarter
- Apogee Therapeutics IncCUSIP 03770N101 was $92.6M
- Ascendis Pharma A/SCUSIP 04351P101 was $85.8M
- SRRKScholar Rock Holding Corp was $65.1M
- VERAVera Therapeutics Inc was $55.0M
- Terns Pharmaceuticals IncCUSIP 880881107 was $52.7M
- BSXBoston Scientific Corp was $50.2M
- Nuvalent IncCUSIP 670703107 was $49.4M
- COGTCogent Biosciences Inc was $47.4M
- CLDXCelldex Therapeutics Inc was $38.8M
- KalVista Pharmaceuticals IncCUSIP 483497103 was $37.2M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +22.3% | +14.8% |
| March 31, 2026 | +11.8% | −4.6% |
| December 31, 2025 | +27.9% | +2.4% |
| September 30, 2025 | +28.4% | +7.8% |
| June 30, 2025 | +3.0% | +10.5% |
| March 31, 2025 | −9.0% | −4.6% |
| December 31, 2024 | −9.7% | +2.1% |
| September 30, 2024 | +13.7% | +5.4% |
| June 30, 2024 | −4.0% | +4.0% |
| March 31, 2024 | +5.1% | +10.0% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Vestal Point Capital, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1974915&type=13F-HR&dateb=&owner=include&count=40CIK 1974915
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1974915/000197491526000005/Filed August 14, 2026 · accession 0001974915-26-000005